| 產(chǎn)品詳情 |
| Edit |   |
|---|
| Product Name | Laquinimod |
|---|
| Description | An orally bioavailable immunomodulator; induces expression of genes related to antigen presentation and inflammatory pathways in human PBMCs in vitro (0.1 μM); decreases the severity of symptoms by 91.4% and the number of relapses in mouse models of aEAE and crEAE, respectively (5 mg/kg per day); decreases T cell and macrophage density and demyelination in the spinal cord of EAE mice compared to non-treated controls (5 mg/kg per day); decreases inflammatory lesions and demyelination in the sciatic nerve in a rat EAN model (12.5 and 25 mg/kg per day); activates gene expression in the AhR pathway in splenocytes from EAE mice with no effect in AhR knockout mice (25 mg/kg per day) |
|---|
| Size | 250 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | ABR-215062 |
|---|
| Gene, Accession, CAS # | CAS: 248281-84-7 |
|---|
| Catalog # | 24187-250 |
|---|
| Price | |
|---|
| Order / More Info | Laquinimod from CAYMAN CHEMICAL COMPANY |
|---|
| Product Specific References | n/a |
|---|
| 產(chǎn)品資料 |
|
|